OHR/AVR118 an immunomodulator which modulates cellular pro-inflammatory chemokine and cykotine synthesis, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).
The company said OHR/AVR118 has powerful chemoprotective effects which allows patients to tolerate higher doses, and more intensive treatment regimens, with toxic chemotherapeutic agents.
Ohr Pharmaceutical CEO Irach Taraporewala said the new patent further strengthens its intellectual property coverage on OHR/AVR118 for its lead indication, cancer cachexia.
"Our phase II trial in this indication is ongoing and we are excited about the continued progress of the program and its potential to meet this unmet medical need." Taraporewala said.
Ohr was previously granted US, Israel, China, and Mexico patent protection for this intellectual property, with applications pending in Europe.
Ohr Pharmaceutical is developing two drugs OHR/AVR 118 and EVIZON Squalamine for the treatment of the wet form of age-related macular degeneration (Wet-AMD).